271 related articles for article (PubMed ID: 35954348)
1. Human Malignant Rhabdoid Tumor Antigens as Biomarkers and Potential Therapeutic Targets.
Hua T; Zeng Z; Chen J; Xue Y; Li Y; Sang Q
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954348
[TBL] [Abstract][Full Text] [Related]
2. Modeling human brain rhabdoid tumor by inactivating tumor suppressor genes in induced pluripotent stem cells.
Hua T; Xue Y; Sarker DB; Kiran S; Li Y; Sang QA
Bioact Mater; 2024 Jan; 31():136-150. PubMed ID: 37637078
[TBL] [Abstract][Full Text] [Related]
3. SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors.
Jeibmann A; Schulz J; Eikmeier K; Johann PD; Thiel K; Tegeder I; Ambrée O; Frühwald MC; Pfister SM; Kool M; Paulus W; Hasselblatt M
J Neurooncol; 2017 Feb; 131(3):477-484. PubMed ID: 28108836
[TBL] [Abstract][Full Text] [Related]
4. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
[TBL] [Abstract][Full Text] [Related]
6. Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup.
Johann PD; Bens S; Oyen F; Wagener R; Giannini C; Perry A; Raisanen JM; Reis GF; Nobusawa S; Arita K; Felsberg J; Reifenberger G; Agaimy A; Buslei R; Capper D; Pfister SM; Schneppenheim R; Siebert R; Frühwald MC; Paulus W; Kool M; Hasselblatt M
Am J Surg Pathol; 2018 Apr; 42(4):506-511. PubMed ID: 29324471
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
[TBL] [Abstract][Full Text] [Related]
8. Ewing Sarcoma and Atypical Teratoid Rhabdoid Tumor: A FISH and Immunohistochemical Comparison.
Pacheco MC; Dolan M; Bendel A
Pediatr Dev Pathol; 2017; 20(5):381-386. PubMed ID: 28382842
[TBL] [Abstract][Full Text] [Related]
9. Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup.
Zin F; Cotter JA; Haberler C; Dottermusch M; Neumann J; Schüller U; Schweizer L; Thomas C; Nemes K; Johann PD; Kool M; Frühwald MC; Paulus W; Judkins A; Hasselblatt M
Brain Pathol; 2021 Sep; 31(5):e12967. PubMed ID: 33938067
[TBL] [Abstract][Full Text] [Related]
10. Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population.
Nemes K; Johann PD; Steinbügl M; Gruhle M; Bens S; Kachanov D; Teleshova M; Hauser P; Simon T; Tippelt S; Eberl W; Chada M; Lopez VS; Grigull L; Hernáiz-Driever P; Eyrich M; Pears J; Milde T; Reinhard H; Leipold A; van de Wetering M; Gil-da-Costa MJ; Ebetsberger-Dachs G; Kerl K; Lemmer A; Boztug H; Furtwängler R; Kordes U; Vokuhl C; Hasselblatt M; Bison B; Kröncke T; Melchior P; Timmermann B; Gerss J; Siebert R; Frühwald MC
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565313
[No Abstract] [Full Text] [Related]
11. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors.
Pathak R; Zin F; Thomas C; Bens S; Gayden T; Karamchandani J; Dudley RW; Nemes K; Johann PD; Oyen F; Kordes U; Jabado N; Siebert R; Paulus W; Kool M; Frühwald MC; Albrecht S; Kalpana GV; Hasselblatt M
Acta Neuropathol; 2021 Aug; 142(2):361-374. PubMed ID: 34003336
[TBL] [Abstract][Full Text] [Related]
13. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome.
Johann PD; Hovestadt V; Thomas C; Jeibmann A; Heß K; Bens S; Oyen F; Hawkins C; Pierson CR; Aldape K; Kim SP; Widing E; Sumerauer D; Hauser P; van Landeghem F; Ryzhova M; Korshunov A; Capper D; Jones DTW; Pfister SM; Schneppenheim R; Siebert R; Paulus W; Frühwald MC; Kool M; Hasselblatt M
Brain Pathol; 2017 Jul; 27(4):411-418. PubMed ID: 27380723
[TBL] [Abstract][Full Text] [Related]
14. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
[TBL] [Abstract][Full Text] [Related]
15. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
[TBL] [Abstract][Full Text] [Related]
16. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
[TBL] [Abstract][Full Text] [Related]
17. Targeting of cyclin-dependent kinases in atypical teratoid rhabdoid tumors with multikinase inhibitor TG02.
Ding AS; Huq S; Casaos J; Raj D; Morales M; Zhao T; Kim T; Srivastava S; Pant A; Serra R; Gorelick NL; Brem H; Tyler B
J Neurosurg Pediatr; 2021 Sep; 28(6):734-743. PubMed ID: 34479190
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
[TBL] [Abstract][Full Text] [Related]
19. The PARP inhibitor Rucaparib synergizes with radiation to attenuate atypical teratoid rhabdoid tumor growth.
Alimova I; Murdock G; Pierce A; Wang D; Madhavan K; Brunt B; Venkataraman S; Vibhakar R
Neurooncol Adv; 2023; 5(1):vdad010. PubMed ID: 36915612
[TBL] [Abstract][Full Text] [Related]
20. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.
Frühwald MC; Hasselblatt M; Nemes K; Bens S; Steinbügl M; Johann PD; Kerl K; Hauser P; Quiroga E; Solano-Paez P; Biassoni V; Gil-da-Costa MJ; Perek-Polnik M; van de Wetering M; Sumerauer D; Pears J; Stabell N; Holm S; Hengartner H; Gerber NU; Grotzer M; Boos J; Ebinger M; Tippelt S; Paulus W; Furtwängler R; Hernáiz-Driever P; Reinhard H; Rutkowski S; Schlegel PG; Schmid I; Kortmann RD; Timmermann B; Warmuth-Metz M; Kordes U; Gerss J; Nysom K; Schneppenheim R; Siebert R; Kool M; Graf N
Neuro Oncol; 2020 Jul; 22(7):1006-1017. PubMed ID: 31883020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
